Literature DB >> 23716059

Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.

A Espinel-Ingroff1, A Chowdhary, G M Gonzalez, C Lass-Flörl, E Martin-Mazuelos, J Meis, T Peláez, M A Pfaller, J Turnidge.   

Abstract

Epidemiological cutoff values (ECVs) were established for the new triazole isavuconazole and Aspergillus species wild-type (WT) MIC distributions (organisms in a species-drug combination with no detectable acquired resistance mechanisms) that were defined with 855 Aspergillus fumigatus, 444 A. flavus, 106 A. nidulans, 207 A. niger, 384 A. terreus, and 75 A. versicolor species complex isolates; 22 Aspergillus section Usti isolates were also included. CLSI broth microdilution MIC data gathered in Europe, India, Mexico, and the United States were aggregated to statistically define ECVs. ECVs were 1 μg/ml for the A. fumigatus species complex, 1 μg/ml for the A. flavus species complex, 0.25 μg/ml for the A. nidulans species complex, 4 μg/ml for the A. niger species complex, 1 μg/ml for the A. terreus species complex, and 1 μg/ml for the A. versicolor species complex; due to the small number of isolates, an ECV was not proposed for Aspergillus section Usti. These ECVs may aid in detecting non-WT isolates with reduced susceptibility to isavuconazole due to cyp51A (an A. fumigatus species complex resistance mechanism among the triazoles) or other mutations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23716059      PMCID: PMC3719700          DOI: 10.1128/AAC.00636-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.

Authors:  Juliette Pavie; Claire Lacroix; Dea Garcia Hermoso; Marie Robin; Christèle Ferry; Anne Bergeron; Martine Feuilhade; Françoise Dromer; Eliane Gluckman; Jean-Michel Molina; Patricia Ribaud
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 2.  Aspergillosis: spectrum of disease, diagnosis, and treatment.

Authors:  Penelope D Barnes; Kieren A Marr
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

3.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

4.  Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA.

Authors:  N Osherov; D P Kontoyiannis; A Romans; G S May
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

5.  Increased resistance to 14 alpha-demethylase inhibitors (DMIs) in Aspergillus niger by coexpression of the Penicillium italicum eburicol 14 alpha-demethylase (cyp51) and the A. niger cytochrome P450 reductase (cprA) genes.

Authors:  H J van den Brink; H J van Nistelrooy; M A de Waard; C A van den Hondel; R F van Gorcom
Journal:  J Biotechnol       Date:  1996-08-20       Impact factor: 3.307

6.  In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

Authors:  H Seifert; U Aurbach; D Stefanik; O Cornely
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

7.  In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration.

Authors:  Maiken C Arendrup; Rasmus H Jensen; Katharina Grif; Marianne Skov; Tacjana Pressler; Helle K Johansen; Cornelia Lass-Flörl
Journal:  J Infect Dis       Date:  2012-07-10       Impact factor: 5.226

Review 8.  Invasive aspergillosis caused by Aspergillus ustus: case report and review.

Authors:  P E Verweij; M F van den Bergh; P M Rath; B E de Pauw; A Voss; J F Meis
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

9.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

10.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Authors:  Peter A Warn; Andrew Sharp; Juan Mosquera; Jochen Spickermann; Anne Schmitt-Hoffmann; Markus Heep; David W Denning
Journal:  J Antimicrob Chemother       Date:  2006-10-27       Impact factor: 5.758

View more
  35 in total

1.  Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad Taghi Hedayati; Saham Ansari; Saeed Mahdavi Omran; Sasan Saber; Haleh Rafati; Jan Zoll; Henrich A van der Lee; Willem J G Melchers; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 2.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

3.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

4.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

5.  Identification by Molecular Methods and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Antifungal Susceptibility Profiles of Clinically Significant Rare Aspergillus Species in a Referral Chest Hospital in Delhi, India.

Authors:  Aradhana Masih; Pradeep K Singh; Shallu Kathuria; Kshitij Agarwal; Jacques F Meis; Anuradha Chowdhary
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

6.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

7.  Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Matthew W McCarthy; Laura L Kovanda; Myo H Zaw; Kaiser Hussain; Naima Shaikh; Bo Bo W Maung; Navjot K Sekhon; William W Hope; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

Authors:  Laura L Kovanda; Ruta Petraitiene; Vidmantas Petraitis; Thomas J Walsh; Amit Desai; Peter Bonate; William W Hope
Journal:  J Antimicrob Chemother       Date:  2016-04-15       Impact factor: 5.790

9.  Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.

Authors:  Susan J Howard; Cornelia Lass-Flörl; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maiken C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

10.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.